Rezdiffra Uptake Held Up By Payers, But Not Biopsy Requirements

Several factors are delaying fulfillment of MASH prescriptions, but payers are not holding out for biopsy disease confirmation. KOLs cited by Leerink also call tirzepatide the clear standout in obesity, though access issues are still an issue.

Frederic Muller/Shutterstock.com
KOLs expect incretins to hold large market share in obesity, MASH

Initial prescriptions for Madrigal Pharmaceuticals, Inc.’s Rezdiffra (resmetirom) are running into payer-related delays, but not because payers want biopsy-based disease confirmation, according to key opinion leaders discussing the metabolic dysfunction-associated steatohepatitis (MASH) and obesity treatment landscapes at a recent Leerink Partners event. Meanwhile, a note issued by Leerink on 14 July cited KOLs saying Eli Lilly and Company’s Zepbound (tirzepatide) offers the best overall clinical profile in obesity therapy.

During an inflammation and immunology therapeutics forum convened by Leerink on 9 July, the firm’s analysts interviewed a pair of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By 

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By 

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Europe’s Drugmakers Lament EU Pharma Package

 
• By 

EFPIA says reforms make the continent less attractive for innovative firms.

More from Scrip

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.